BD (Becton, Dickinson and Company) announced its BD® CentroVena One™ Insertion System received an Innovative Technology contract from Vizient, recognizing its breakthrough design that simplifies central line insertion and enhances patient and clinician safety. The all-in-one system integrates multiple components, reducing procedural steps by 30% and cutting maximum procedure time by 50%, while lowering risks like contamination and needlestick injuries. This award highlights the system's potential to improve healthcare delivery and workflow efficiency, with Vizient's client-led councils endorsing its innovation. BD plans to expand access to this technology among Vizient's broad healthcare client base.

More News (BDX)

Enteric disease testing market to grow to $5.86B by 2035, driven by foodborne disease surveillance and molecular diagnostics.

The global enteric disease testing market is projected to grow from $4.08 billion in 2025 to $5.86 billion by 2035, at a CAGR of 3.7%. Growth is fueled by rising foodborne and waterborne diseases, demand for rapid pathogen detection, and adoption of ...

Market News

Bullish

1 day ago

BD's CentroVena One™ wins Vizient Innovative Technology contract for safer, simpler central line insertion.

More News (BDX)

Enteric disease testing market to grow to $5.86B by 2035, driven by foodborne disease surveillance and molecular diagnostics.

Invest & Trade with
#1 Award-Winning Investment Super App

Invest

Features

Fees

Learn

Investment Clubs (Coming Soon)

Support

iOS App Store

Google Play Store

BD's CentroVena One™ wins Vizient Innovative Technology contract for safer, simpler central line insertion.

More News (BDX)

Enteric disease testing market to grow to $5.86B by 2035, driven by foodborne disease surveillance and molecular diagnostics.

Invest & Trade with#1 Award-Winning Investment Super App

iOS App Store

Google Play Store

Invest & Trade with
#1 Award-Winning Investment Super App